GoSite Raises $40M Series B To Bring Small Businesses Online

Growth funding positions small business platform for continued momentum and expansion

SAN DIEGO, Dec. 1, 2020 /PRNewswire/ -- GoSite, the all-in-one platform helping small businesses grow online, announced today that it has closed a $40 million Series B fundraising round led by New York-based Left Lane Capital. The easy-to-use application gives businesses the strong digital presence they need to engage and transact with customers online. The robust product suite enables businesses to manage their website, listings, reviews, messages, booking and payments, all in one platform. From landscapers to hair salons and auto shops, GoSite helps businesses transition online and enable their customers to book, pay and review services seamlessly. 

"GoSite puts the power back in the hands of small business owners," said Alex Goode, GoSite CEO. "Millions of small businesses are facing the need to transition into the digital era, and we're excited to continue building the technology that makes this possible." 

The investment comes from Left Lane Capital, an emerging New York-based growth fund started by an ex-Insight Partners team. Left Lane invests in high-growth internet companies globally. 

"Small business owners have to do five things at once," said Vinny Pujji, partner at Left Lane and San Diego native. "Alex and his team have built a powerful, broad solution that manages to be simple enough for a one-person operation. We're thrilled to support GoSite on their mission to make traditionally offline small businesses successful in the digital age." 

Longley Capital, Cove Fund, Stage 2, Ankona Capital and Serra Ventures also participated in this round. 

Momentum Fuels Expanded Offerings, Customer Growth

Small businesses face many unique challenges, exacerbated as the world continues to experience impact caused by the COVID-19 pandemic. In an age when most business is conducted online, GoSite has helped thousands of merchants stay open and continue to be found, booked and paid by their customers. So far in 2020, GoSite has doubled its customer base, reaching thousands of small businesses that have turned to the platform to bring their business online and manage it on the go. GoSite's offering for small businesses is expansive, as partnerships with platforms such as Shutterstock have increased reach and positioned the startup for exponential growth. 

The Series B funding will allow GoSite to expand its product offerings to help more businesses as they adapt during COVID-19, as well as scale operations to continue to offer a world-class customer experience. Businesses now have expanded free trial access to premium products, such as GoSite's suite of Payments tools, that make it easier for merchants to accept credit cards, receive digital payments, create invoices and more. GoSite's platform enables safe, contactless payments, overcoming a significant hurdle millions of business owners currently face. 

Capital Raise

The $40 million Series B investment will fuel GoSite's continued expansion and development of innovative products for small businesses as well as hire exceptional talent. This round follows shortly on the heels of a Series A round earlier this year, bringing the San Diego-based startup to a total $56 million investment in 2020, an exciting infusion of resources dedicated to helping small businesses grow. 

About GoSite

GoSite is a robust digital platform for the 12 million small businesses providing local services in the U.S. The platform helps these businesses make the transition from offline to online by giving them everything they need to connect with customers in the digital era. The all-in-one, cloud-based platform and mobile app transforms the way they run their business by making it easier for their customers to attract and transact with their business online. Learn more at gosite.com.

About Left Lane Capital

Left Lane Capital is a New York-based venture capital and growth equity firm, investing in high-growth internet and technology companies that build lasting relationships with customers. The firm invests in Series A-C companies and aims to partner with extraordinary entrepreneurs creating category-defining businesses. Learn more at leftlanecap.com. 

Cove Fund Invests in Dermala's $6.73M Series A Round

Johnson & Johnson Innovation – JJDC, Inc. and True Wealth Ventures co-led the funding round, joined by Seventure Partners and Cove Fund

November 09, 2020 08:00 AM Eastern Standard Time

SAN DIEGO--(BUSINESS WIRE)--DERMALA, Inc., a consumer dermatology company developing novel, personalized, microbiome-based solutions for acne and other skin conditions, announced today that it has closed a $6.73 million Series A financing. The company developed an integrated platform that combines patent-pending microbiome-based topical and oral products containing unique prebiotic, probiotic, and postbiotic ingredients, including the SE Microbiome Complex®, with a proprietary data analytics app that enables personalization and continuous optimization of product formulations based on individual outcomes.

“Exploring the richness of microbiome biology including prebiotics, probiotics and postbiotics, and combining topical and oral products for OTC dermatology makes great scientific sense”

“The consumer dermatology category is ripe for science-based solutions to treat common skin conditions,” said Lada Rasochova, Ph.D., MBA, Founder and CEO of DERMALA. “One size just does not fit all when it comes to acne. Most acne treatments have been on the market for decades, but they do not work for everyone. Our proprietary platform combines human microbiome science with data analytics to identify product formulations that deliver the best results and help our customers feel confident, healthy and beautiful in their skin.”

DERMALA launched its #FOBO® (Fear of Breaking Out) Kit, a microbiome-based solution for acne in 2019. It has attracted many loyal customers who value its personalized approach to helping them conquer their “fear of breaking out”. The solution comprises topical acne treatments and oral supplements paired with the DERMALA Acne Tracker app, which customers use to track their skin health.

The Series A financing was co-led by Johnson & Johnson Innovation – JJDC, Inc. and True Wealth Ventures. Seventure Partners, investing via their Health for Life Capital™ Funds, and Cove Fund joined the financing round.

“DERMALA brings together science-based products with robust data analytics to deliver value to the customer with a unique skin health solution,” said Sara T. Brand, Founding General Partner of True Wealth Ventures. “The app enables DERMALA’s product customization and helps customers with treatment compliance. It is truly unique within the OTC consumer dermatology category.”

“Exploring the richness of microbiome biology including prebiotics, probiotics and postbiotics, and combining topical and oral products for OTC dermatology makes great scientific sense,” said Isabelle de Crémoux, CEO and Managing Partner of Seventure Partners. “This, combined with creative marketing and a personalized digital program, positions DERMALA for success after this Series A investment and will allow them to scale up their operations and reach more people in need.”

DERMALA will use the proceeds of the funding round to scale operations, manufacturing, and commercial efforts for its acne products. It will also expand its research and development activities exploring new personalized microbiome-based products for other skin conditions including eczema and skin wellness.

About DERMALA

DERMALA, Inc. is a privately-held consumer dermatology company leveraging scientific understanding of the human microbiome to develop novel solutions for acne and other skin conditions. The company’s #FOBO® (Fear of Breaking Out) Kit, a personalized microbiome-based solution for acne, combines patent-pending topical acne treatments with oral supplements and a proprietary DERMALA Acne Tracker app that customers use to track their skin health. For more information, visit dermala.com.

DERMALA Announces $6.73 Million Series A Financing to Expand and Scale Company’s Personalized Microbiome-Based Solutions for Acne and Other Skin Conditions

November 09, 2020 08:00 AM Eastern Standard Time

SAN DIEGO--(BUSINESS WIRE)--DERMALA, Inc., a consumer dermatology company developing novel, personalized, microbiome-based solutions for acne and other skin conditions, announced today that it has closed a $6.73 million Series A financing. The company developed an integrated platform that combines patent-pending microbiome-based topical and oral products containing unique prebiotic, probiotic, and postbiotic ingredients, including the SE Microbiome Complex®, with a proprietary data analytics app that enables personalization and continuous optimization of product formulations based on individual outcomes.

“Exploring the richness of microbiome biology including prebiotics, probiotics and postbiotics, and combining topical and oral products for OTC dermatology makes great scientific sense”

“The consumer dermatology category is ripe for science-based solutions to treat common skin conditions,” said Lada Rasochova, Ph.D., MBA, Founder and CEO of DERMALA. “One size just does not fit all when it comes to acne. Most acne treatments have been on the market for decades, but they do not work for everyone. Our proprietary platform combines human microbiome science with data analytics to identify product formulations that deliver the best results and help our customers feel confident, healthy and beautiful in their skin.”

DERMALA launched its #FOBO® (Fear of Breaking Out) Kit, a microbiome-based solution for acne in 2019. It has attracted many loyal customers who value its personalized approach to helping them conquer their “fear of breaking out”. The solution comprises topical acne treatments and oral supplements paired with the DERMALA Acne Tracker app, which customers use to track their skin health.

The Series A financing was co-led by Johnson & Johnson Innovation – JJDC, Inc. and True Wealth Ventures. Seventure Partners, investing via their Health for Life Capital™ Funds, and Cove Fund joined the financing round.

“DERMALA brings together science-based products with robust data analytics to deliver value to the customer with a unique skin health solution,” said Sara T. Brand, Founding General Partner of True Wealth Ventures. “The app enables DERMALA’s product customization and helps customers with treatment compliance. It is truly unique within the OTC consumer dermatology category.”

“Exploring the richness of microbiome biology including prebiotics, probiotics and postbiotics, and combining topical and oral products for OTC dermatology makes great scientific sense,” said Isabelle de Crémoux, CEO and Managing Partner of Seventure Partners. “This, combined with creative marketing and a personalized digital program, positions DERMALA for success after this Series A investment and will allow them to scale up their operations and reach more people in need.”

DERMALA will use the proceeds of the funding round to scale operations, manufacturing, and commercial efforts for its acne products. It will also expand its research and development activities exploring new personalized microbiome-based products for other skin conditions including eczema and skin wellness.

About DERMALA

DERMALA, Inc. is a privately-held consumer dermatology company leveraging scientific understanding of the human microbiome to develop novel solutions for acne and other skin conditions. The company’s #FOBO® (Fear of Breaking Out) Kit, a personalized microbiome-based solution for acne, combines patent-pending topical acne treatments with oral supplements and a proprietary DERMALA Acne Tracker app that customers use to track their skin health. For more information, visit dermala.com.

Cove Fund Invests in Daasity’s $2.3M Seed Round

FOR IMMEDIATE RELEASE - November 6, 2019 - San Diego, CA

Daasity’s Data Analytics Solution Makes Business-Critical Data Accessible for Direct-to-Consumer Companies 

SAN DIEGO – (Nov. 6, 2019) – Daasity, an end-to-end data analytics solution provider for direct-to-consumer (DTC) retailers, has successfully raised $2.3M in its first round of funding. Daasity is the first company to design a proprietary platform that addresses the critical steps of data extraction, transformation, and analysis to give end users access to business data and metrics. The platform gives companies the capability to use data more strategically, make data-informed decisions and ultimately grow their businesses without hiring technical staff.

Daasity’s debut funding was oversubscribed and led by Okapi Venture Capital.  Serra Ventures, Cove Fund II, 1855 Capital, and Mooring Ventures LLC also participated in the round.

Daasity’s “D2C Analytics Suite” ingests, re-structures and transforms data automatically, without the need for hiring costly staff. It provides a holistic view across all key business areas and unlocks valuable insights, saving brands both time and money.

The 12 standard dashboards that come with the D2C Suite give immediate access to metrics around business health, omnichannel measurement, marketing efficacy, customers, product/inventory management, and more. All without the need to hire analysts to build queries and reports.

After ingesting, transforming and organizing additional data from platforms like Shopify, Amazon and Facebook, it unifies and pushes all the combined data to a visualization tool that answers the most important business questions in the moment.

“Data is one of the most important assets a company has. Yet effectively using it, ensuring its cleanliness and trusting its accuracy is a challenge for many companies,” said Dan LeBlanc, Daasity CEO and Co-Founder. “Our philosophy is that having access to comprehensive data shouldn’t cost six figures and take months for implementation.”

As a young start-up, Daasity has already made significant strides and generated notable revenue. The company is quickly becoming known as the go-to solution in the Shopify Plus community. Forty top DTC brands across the U.S. are using the solution to accelerate their revenue growth, including Kopari, BioClarity, MVMT Watches, Parachute Home, and Rothy’s.

“The Daasity platform has helped fuel our 100 percent-plus year-over-year growth,” said Jameson Slattery, Operating Partner at Kopari, a Daasity client. “Insights from the Daasity platform have highlighted key levers and programs in our business that drive the most profitable growth.”

"We've backed Daasity because no other company has developed a platform that gives retailers cutting-edge access to data and a single source of truth for confident, strategic decision-making,” said Jeff Bocan, Partner at Okapi Venture Capital. “The demand for this kind of comprehensive data is enormous, and Daasity is positioned for accelerated growth as the company launches additional predictive analytics products in 2020.”

For more information or a demo, visit www.Daasity.com.

About Daasity

Daasity is transforming the way companies access and use their data. It is the first and only company to design a proprietary platform specifically for the direct-to-consumer industry that makes business-critical data accessible and usable for strategic decision-making. The company’s mission is to make business-critical data accessible for all DTC brands. Visit www.Daasity.com or LinkedIn.